贤丰控股(002141) - 2022 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2022 was ¥885,746,851.76, a decrease of 39.73% compared to ¥1,469,710,678.10 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥232,296,378.74, representing a significant increase of 695.80% from ¥29,190,245.40 in 2021[21]. - The net cash flow from operating activities was ¥20,900,600.38, up 99.36% from ¥10,483,842.83 in 2021[21]. - The basic earnings per share for 2022 was ¥0.2047, a 696.50% increase from ¥0.0257 in 2021[21]. - The total assets at the end of 2022 were ¥1,343,332,102.28, a decrease of 3.70% from ¥1,394,959,827.53 at the end of 2021[21]. - The net assets attributable to shareholders increased by 42.61% to ¥1,146,062,191.42 at the end of 2022, compared to ¥803,637,142.31 at the end of 2021[21]. - The company reported a quarterly revenue of ¥19,178,280.84 in Q4 2022, a significant drop compared to previous quarters[25]. - The net profit attributable to shareholders in Q3 2022 was ¥225,227,221.05, but turned negative in Q4 with a loss of ¥16,318,132.23[25]. - Non-operating income from government subsidies was ¥4,009,707.85 in 2022, down from ¥10,539,869.56 in 2021[26]. - The company recognized a total of ¥320,163,639.11 in non-recurring gains in 2022, compared to ¥13,988,698.40 in 2021[27]. Business Strategy and Operations - The main business has shifted to veterinary vaccine operations after divesting from the fine enameled wire business[19]. - The company completed the sale of equity in Zhuhai Rongsheng, marking a strategic exit from the fine enameled wire sector[19]. - The company strategically exited the micro-fine enameled wire business following the completion of a major asset sale by the end of Q3 2022[30]. - The domestic animal vaccine market is expected to enter a rapid growth phase, driven by increased awareness of prevention and government emphasis on animal health[31]. - The core product of Shiji Biological is pig vaccines, with a significant correlation to the trends in the pig farming industry, which experienced a volatile price pattern in 2022[31]. - Shiji Biological has developed six core pig vaccine products and five professional services, maintaining a strong market reputation[32]. - The company has established a comprehensive procurement management system to reduce costs while ensuring quality stability[32]. - The company has developed several innovative vaccine quality evaluation methods, which have received high recognition in the industry, including awards for the RFFIT neutralization antibody detection method[43]. - The company is actively exploring the lithium-ion battery supply chain, with a 30,000 tons/year industrial-grade lithium carbonate project currently in the preparatory stage[44]. - The company launched two new products, the inactivated canine parvovirus vaccine and the inactivated streptococcus vaccine, further enriching its product line[43]. Risk Management and Compliance - The annual report includes a section on potential risks and countermeasures related to future business operations[3]. - The report highlights the importance of investor awareness regarding the differences between plans, forecasts, and commitments[3]. - The company is facing significant challenges in its veterinary vaccine business due to market fluctuations and a decline in customer orders[40]. - The company emphasizes the importance of monitoring macroeconomic conditions and adjusting operational strategies accordingly to improve competitiveness and risk resistance[86]. - The company has maintained compliance with corporate governance regulations, ensuring that all shareholders, especially minority shareholders, can exercise their rights without harm[91]. - The company has established independent financial management systems and maintains separate financial operations from its controlling shareholder[96]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, meeting legal requirements for governance structure[92]. - The company has a diverse management team with backgrounds in finance, law, and engineering, enhancing its strategic capabilities[101][102][103]. - The company emphasizes the importance of financial expertise in its leadership, as evidenced by the qualifications of its financial director and independent directors[100][102]. - The total remuneration for directors, supervisors, and senior management amounted to CNY 573.1 million for the reporting period[108]. - The company has a structured remuneration decision-making process involving the remuneration and assessment committee, board of directors, and shareholders' meeting[107]. Environmental Responsibility - The company has implemented a wastewater treatment facility with a capacity of 700m³/d, ensuring compliance with discharge standards[133]. - The company operates a low-nitrogen combustion boiler to reduce nitrogen oxide emissions, with an additional low-nitrogen boiler installation in progress[133]. - The company has established measures for noise control to ensure compliance with noise discharge standards[133]. - The company has a zero occurrence of exceeding pollutant discharge limits throughout the year[132]. - Zhuhai Rongseng invested a total of 2.8908 million yuan in 136 new organic waste gas treatment facilities, expected to reduce VOCs emissions by 4.327 tons per year[134]. Shareholder Relations - The company has a profit distribution policy in place, but did not propose any cash dividend distribution during the reporting period despite having positive distributable profits[121]. - The controlling shareholder, Xianfeng Group, commits to maintaining the independence of the listed company and ensuring no improper benefits are obtained from its controlling position[152]. - The company guarantees that it will not interfere with management activities or infringe on company interests during the asset restructuring process[155]. - The company will avoid any actions that could harm the interests of minority shareholders during the restructuring process[162]. Legal and Regulatory Matters - The company has no significant litigation or arbitration matters that would impact its financial status[173]. - The company has engaged Beijing Xinghua Accounting Firm for auditing services, with a fee of 650,000 RMB for the reporting period[171]. - The company reported a total of 3,357.99 million in litigation cases, with 41 cases already adjudicated or mediated[174].